Skip to main content
Premium Trial:

Request an Annual Quote

Amaxa to Oversee EU-Funded Effort to Develop Primary Cell Transfection Device

NEW YORK (GenomeWeb News) — Amaxa said today that it will coordinate an eight-member European alliance to develop devices for ultra-high-throughput transfection of primary cells.
The European Commission awarded the partnership more than €2.75 million ($3.7 million) in funding. The group will use Amaxa’s Nucleofector technology, the company said.
 
Amaxa said the development project, termed Modest-EU, is expected to last three years and includes Deutsches Rheumaforschungszentrum, RNAx, Protobios, Fotec, HTP High Tech Plastics, Dominion Pharmakine, and Prevas.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.